Experienced in Chronic Pain

Dr. Randall J. Severance

Internal Medicine
924 W Chandler Blvd, 
Chandler, AZ 
Experienced in Chronic Pain
924 W Chandler Blvd, 
Chandler, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Randall Severance is a primary care provider, practicing in Internal Medicine in Chandler, Arizona. Dr. Severance is rated as an Experienced provider by MediFind in the treatment of Chronic Pain. His top areas of expertise are Chronic Pain, Togaviridae Disease, Non-Alcoholic Fatty Liver Disease, and Neuralgia.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 6 clinical trials in the study of Chronic Pain.

Specialties
Internal Medicine
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO

Locations

924 W Chandler Blvd, Chandler, AZ 85225

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Terminated
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug
Study Drug: LY3526318
Study Phase: Phase 2
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 15 Less Clinical Trials

4 Total Publications

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Journal: Human vaccines & immunotherapeutics
Published: November 02, 2021
Similar Doctors
Advanced in Chronic Pain
Dr. Louise A. Taber
Internal Medicine
Advanced in Chronic Pain
Dr. Louise A. Taber
Internal Medicine
2525 W Greenway Rd, Suite 114, 
Phoenix, AZ 
 (26.4 miles away)
602-863-6363
Languages Spoken:
English
See accepted insurances

Louise Taber is a primary care provider, practicing in Internal Medicine in Phoenix, Arizona. Dr. Taber is rated as an Advanced provider by MediFind in the treatment of Chronic Pain. Her top area of expertise is Chronic Pain.

Advanced in Chronic Pain
Dr. Ashish Sachdeva
Internal Medicine
Advanced in Chronic Pain
Dr. Ashish Sachdeva
Internal Medicine

Surraj Medical Associates PLLC

9401 W Thunderbird Rd, Suite 155, 
Peoria, AZ 
 (31.2 miles away)
623-249-2100
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ashish Sachdeva is a primary care provider, practicing in Internal Medicine in Peoria, Arizona. Dr. Sachdeva is rated as an Advanced provider by MediFind in the treatment of Chronic Pain. His top areas of expertise are Cerebellar Degeneration, Vitamin B12 Deficiency, Glossitis, and Pernicious Anemia. Dr. Sachdeva is currently accepting new patients.

Advanced in Chronic Pain
Dr. Aureliano E. Cifuentes
Geriatrics | Family Medicine | Internal Medicine
Advanced in Chronic Pain
Dr. Aureliano E. Cifuentes
Geriatrics | Family Medicine | Internal Medicine

Gila Internal Medicine And Geriatric P C

2727 W Baseline Rd, Suite 8, 
Tempe, AZ 
 (8.4 miles away)
602-323-0904
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Aureliano Cifuentes is a primary care provider, practicing in Geriatrics and Internal Medicine in Tempe, Arizona. Dr. Cifuentes is rated as a Distinguished provider by MediFind in the treatment of Chronic Pain. His top areas of expertise are Osteomyelitis in Children, Type 2 Diabetes (T2D), High Cholesterol, and Hypertensive Heart Disease. Dr. Cifuentes is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Severance's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile